Loading clinical trials...
Loading clinical trials...
A Multicenter, 18-week Open Label Safety and Efficacy Trial of Dalfampridine in Primary Lateral Sclerosis
Conditions
Interventions
dalfampridine
Locations
3
United States
University of Florida Gainsville
Gainesville, Florida, United States
Mass General Hospital
Boston, Massachusetts, United States
Shara Holzberg
New York, New York, United States
Start Date
March 1, 2016
Primary Completion Date
July 1, 2026
Completion Date
July 1, 2026
Last Updated
September 11, 2025
Lead Sponsor
Hospital for Special Surgery, New York
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions